1.1.................... moves to amend S.F. No. 3560, the second engrossment, as follows:
1.2Page 9, after line 8, insert:

1.3    "Sec. 12. Minnesota Statutes 2018, section 152.01, subdivision 23, is amended to read:
1.4    Subd. 23. Analog. (a) Except as provided in paragraph (b), "analog" means a substance,
1.5the chemical structure of which is substantially similar to the chemical structure of a
1.6controlled substance in Schedule I or II:
1.7(1) that has a stimulant, depressant, or hallucinogenic effect on the central nervous system
1.8that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic
1.9effect on the central nervous system of a controlled substance in Schedule I or II; or
1.10(2) with respect to a particular person, if the person represents or intends that the substance
1.11have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is
1.12substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect
1.13on the central nervous system of a controlled substance in Schedule I or II.
1.14(b) "Analog" does not include:
1.15(1) a controlled substance;
1.16(2) any substance for which there is an approved new drug application under the Federal
1.17Food, Drug, and Cosmetic Act; or
1.18(3) with respect to a particular person, any substance, if an exemption is in effect for
1.19investigational use, for that person, as provided by United States Code, title 21, section 355,
1.20and the person is registered as a controlled substance researcher as required under section
1.21152.12, subdivision 3, to the extent conduct with respect to the substance is pursuant to the
1.22exemption and registration; or
2.1(4) marijuana or tetrahydrocannabinols naturally contained in a plant of the genus
2.2cannabis or in the resinous extractives of the plant.
2.3EFFECTIVE DATE.This section is effective August 1, 2020, and applies to crimes
2.4committed on or after that date.

2.5    Sec. 13. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read:
2.6    Subd. 2. Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
2.7(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
2.8following substances, including their analogs, isomers, esters, ethers, salts, and salts of
2.9isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,
2.10and salts is possible:
2.11(1) acetylmethadol;
2.12(2) allylprodine;
2.13(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
2.14acetate);
2.15(4) alphameprodine;
2.16(5) alphamethadol;
2.17(6) alpha-methylfentanyl benzethidine;
2.18(7) betacetylmethadol;
2.19(8) betameprodine;
2.20(9) betamethadol;
2.21(10) betaprodine;
2.22(11) clonitazene;
2.23(12) dextromoramide;
2.24(13) diampromide;
2.25(14) diethyliambutene;
2.26(15) difenoxin;
2.27(16) dimenoxadol;
2.28(17) dimepheptanol;
3.1(18) dimethyliambutene;
3.2(19) dioxaphetyl butyrate;
3.3(20) dipipanone;
3.4(21) ethylmethylthiambutene;
3.5(22) etonitazene;
3.6(23) etoxeridine;
3.7(24) furethidine;
3.8(25) hydroxypethidine;
3.9(26) ketobemidone;
3.10(27) levomoramide;
3.11(28) levophenacylmorphan;
3.12(29) 3-methylfentanyl;
3.13(30) acetyl-alpha-methylfentanyl;
3.14(31) alpha-methylthiofentanyl;
3.15(32) benzylfentanyl beta-hydroxyfentanyl;
3.16(33) beta-hydroxy-3-methylfentanyl;
3.17(34) 3-methylthiofentanyl;
3.18(35) thenylfentanyl;
3.19(36) thiofentanyl;
3.20(37) para-fluorofentanyl;
3.21(38) morpheridine;
3.22(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.23(40) noracymethadol;
3.24(41) norlevorphanol;
3.25(42) normethadone;
3.26(43) norpipanone;
3.27(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
4.1(45) phenadoxone;
4.2(46) phenampromide;
4.3(47) phenomorphan;
4.4(48) phenoperidine;
4.5(49) piritramide;
4.6(50) proheptazine;
4.7(51) properidine;
4.8(52) propiram;
4.9(53) racemoramide;
4.10(54) tilidine;
4.11(55) trimeperidine;
4.12(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
4.13(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
4.14methylbenzamide(U47700);
4.15(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
4.16and
4.17(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol).
4.18(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
4.19and salts of isomers, unless specifically excepted or unless listed in another schedule,
4.20whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
4.21(1) acetorphine;
4.22(2) acetyldihydrocodeine;
4.23(3) benzylmorphine;
4.24(4) codeine methylbromide;
4.25(5) codeine-n-oxide;
4.26(6) cyprenorphine;
4.27(7) desomorphine;
4.28(8) dihydromorphine;
5.1(9) drotebanol;
5.2(10) etorphine;
5.3(11) heroin;
5.4(12) hydromorphinol;
5.5(13) methyldesorphine;
5.6(14) methyldihydromorphine;
5.7(15) morphine methylbromide;
5.8(16) morphine methylsulfonate;
5.9(17) morphine-n-oxide;
5.10(18) myrophine;
5.11(19) nicocodeine;
5.12(20) nicomorphine;
5.13(21) normorphine;
5.14(22) pholcodine; and
5.15(23) thebacon.
5.16(d) Hallucinogens. Any material, compound, mixture or preparation which contains any
5.17quantity of the following substances, their analogs, salts, isomers (whether optical, positional,
5.18or geometric), and salts of isomers, unless specifically excepted or unless listed in another
5.19schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
5.20possible:
5.21(1) methylenedioxy amphetamine;
5.22(2) methylenedioxymethamphetamine;
5.23(3) methylenedioxy-N-ethylamphetamine (MDEA);
5.24(4) n-hydroxy-methylenedioxyamphetamine;
5.25(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
5.26(6) 2,5-dimethoxyamphetamine (2,5-DMA);
5.27(7) 4-methoxyamphetamine;
5.28(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
6.1(9) alpha-ethyltryptamine;
6.2(10) bufotenine;
6.3(11) diethyltryptamine;
6.4(12) dimethyltryptamine;
6.5(13) 3,4,5-trimethoxyamphetamine;
6.6(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
6.7(15) ibogaine;
6.8(16) lysergic acid diethylamide (LSD);
6.9(17) mescaline;
6.10(18) parahexyl;
6.11(19) N-ethyl-3-piperidyl benzilate;
6.12(20) N-methyl-3-piperidyl benzilate;
6.13(21) psilocybin;
6.14(22) psilocyn;
6.15(23) tenocyclidine (TPCP or TCP);
6.16(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
6.17(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
6.18(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
6.19(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
6.20(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
6.21(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
6.22(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
6.23(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
6.24(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
6.25(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
6.26(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
6.27(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
7.1(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
7.2(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
7.3(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
7.4(2-CB-FLY);
7.5(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
7.6(40) alpha-methyltryptamine (AMT);
7.7(41) N,N-diisopropyltryptamine (DiPT);
7.8(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
7.9(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
7.10(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
7.11(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
7.12(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
7.13(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
7.14(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
7.15(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
7.16(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
7.17(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
7.18(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
7.19(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
7.20(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
7.21(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
7.22(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
7.23(57) methoxetamine (MXE);
7.24(58) 5-iodo-2-aminoindane (5-IAI);
7.25(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
7.26(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
7.27(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
8.1(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
8.2(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
8.3(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
8.4(65) N,N-Dipropyltryptamine (DPT);
8.5(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
8.6(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
8.7(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
8.8(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
8.9(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,
8.10ethketamine, NENK);
8.11(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
8.12(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
8.13(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
8.14(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii
8.15Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
8.16and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
8.17its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
8.18apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
8.19Church, and members of the American Indian Church are exempt from registration. Any
8.20person who manufactures peyote for or distributes peyote to the American Indian Church,
8.21however, is required to obtain federal registration annually and to comply with all other
8.22requirements of law.
8.23(f) Central nervous system depressants. Unless specifically excepted or unless listed in
8.24another schedule, any material compound, mixture, or preparation which contains any
8.25quantity of the following substances, their analogs, salts, isomers, and salts of isomers
8.26whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
8.27(1) mecloqualone;
8.28(2) methaqualone;
8.29(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
8.30(4) flunitrazepam; and
9.1(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
9.2methoxyketamine).
9.3(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
9.4material compound, mixture, or preparation which contains any quantity of the following
9.5substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the
9.6analogs, salts, isomers, and salts of isomers is possible:
9.7    (1) aminorex;
9.8(2) cathinone;
9.9(3) fenethylline;
9.10    (4) methcathinone;
9.11(5) methylaminorex;
9.12(6) N,N-dimethylamphetamine;
9.13(7) N-benzylpiperazine (BZP);
9.14(8) methylmethcathinone (mephedrone);
9.15(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
9.16(10) methoxymethcathinone (methedrone);
9.17(11) methylenedioxypyrovalerone (MDPV);
9.18(12) 3-fluoro-N-methylcathinone (3-FMC);
9.19(13) methylethcathinone (MEC);
9.20(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
9.21(15) dimethylmethcathinone (DMMC);
9.22(16) fluoroamphetamine;
9.23(17) fluoromethamphetamine;
9.24(18) α-methylaminobutyrophenone (MABP or buphedrone);
9.25(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
9.26(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
9.27(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
9.28naphyrone);
10.1(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
10.2(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
10.3(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
10.4(25) 4-methyl-N-ethylcathinone (4-MEC);
10.5(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
10.6(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
10.7(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
10.8(29) 4-fluoro-N-methylcathinone (4-FMC);
10.9(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
10.10(31) alpha-pyrrolidinobutiophenone (α-PBP);
10.11(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
10.12(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
10.13(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
10.14(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
10.15(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
10.16(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
10.17(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); and
10.18(39) any other substance, except bupropion or compounds listed under a different
10.19schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
10.201-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
10.21compound is further modified in any of the following ways:
10.22(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
10.23haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
10.24system by one or more other univalent substituents;
10.25(ii) by substitution at the 3-position with an acyclic alkyl substituent;
10.26(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
10.27methoxybenzyl groups; or
10.28(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
11.1(h) Marijuana, Synthetic tetrahydrocannabinols, and synthetic cannabinoids. Unless
11.2specifically excepted or unless listed in another schedule, any natural or synthetic material,
11.3compound, mixture, or preparation that contains any quantity of the following substances,
11.4their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever
11.5the existence of the isomers, esters, ethers, or salts is possible:
11.6(1) marijuana;
11.7(2) synthetic tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
11.8that are the synthetic equivalents of the substances contained in the cannabis plant or in the
11.9resinous extractives of the plant, or synthetic substances with similar chemical structure
11.10and pharmacological activity to those substances contained in the plant or resinous extract,
11.11including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
11.12tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
11.13(3) (2) synthetic cannabinoids, including the following substances:
11.14(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
11.15structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
11.16alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
11.172-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
11.18extent and whether or not substituted in the naphthyl ring to any extent. Examples of
11.19naphthoylindoles include, but are not limited to:
11.20(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
11.21(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
11.22(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
11.23(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
11.24(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
11.25(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
11.26(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
11.27(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
11.28(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
11.29(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
11.30(ii) Napthylmethylindoles, which are any compounds containing a
11.311H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
12.1indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12.21-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
12.3substituted in the indole ring to any extent and whether or not substituted in the naphthyl
12.4ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
12.5(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
12.6(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
12.7(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
12.8structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
12.9alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.102-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
12.11extent, whether or not substituted in the naphthyl ring to any extent. Examples of
12.12naphthoylpyrroles include, but are not limited to,
12.13(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
12.14(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene
12.15structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
12.16cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.172-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any
12.18extent, whether or not substituted in the naphthyl ring to any extent. Examples of
12.19naphthylemethylindenes include, but are not limited to,
12.20E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
12.21(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
12.22structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
12.23alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.242-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
12.25extent, whether or not substituted in the phenyl ring to any extent. Examples of
12.26phenylacetylindoles include, but are not limited to:
12.27(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
12.28(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
12.29(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
12.30(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
12.31(vi) Cyclohexylphenols, which are compounds containing a
12.322-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
12.33ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13.11-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
13.2in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
13.3limited to:
13.4(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
13.5(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
13.6(Cannabicyclohexanol or CP 47,497 C8 homologue);
13.7(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
13.8-phenol (CP 55,940).
13.9(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
13.10with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
13.11cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.122-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
13.13extent and whether or not substituted in the phenyl ring to any extent. Examples of
13.14benzoylindoles include, but are not limited to:
13.15(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
13.16(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
13.17(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
13.1848,098 or Pravadoline).
13.19(viii) Others specifically named:
13.20(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
13.21-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
13.22(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
13.23-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
13.24(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
13.25-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
13.26(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
13.27(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
13.28(XLR-11);
13.29(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
13.30(AKB-48(APINACA));
14.1(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
14.2(5-Fluoro-AKB-48);
14.3(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
14.4(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
14.5(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide
14.6(AB-PINACA);
14.7(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
14.81H-indazole-3-carboxamide (AB-FUBINACA);
14.9(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
14.10indazole-3-carboxamide(AB-CHMINACA);
14.11(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate
14.12(5-fluoro-AMB);
14.13(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
14.14(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone)
14.15(FUBIMINA);
14.16(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
14.17[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
14.18(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
14.19-1H-indole-3-carboxamide (5-fluoro-ABICA);
14.20(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
14.21-1H-indole-3-carboxamide;
14.22(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
14.23-1H-indazole-3-carboxamide;
14.24(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
14.25(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
14.26H-indazole-3-carboxamide (MAB-CHMINACA);
14.27(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
14.28(ADB-PINACA);
14.29(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
15.1(X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
15.23-carboxamide. (APP-CHMINACA);
15.3(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
15.4(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
15.5(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
15.6for human consumption.
15.7EFFECTIVE DATE.This section is effective August 1, 2020, and applies to crimes
15.8committed on or after that date.

15.9    Sec. 14. Minnesota Statutes 2018, section 152.02, subdivision 3, is amended to read:
15.10    Subd. 3. Schedule II. (a) Schedule II consists of the substances listed in this subdivision.
15.11(b) Unless specifically excepted or unless listed in another schedule, any of the following
15.12substances whether produced directly or indirectly by extraction from substances of vegetable
15.13origin or independently by means of chemical synthesis, or by a combination of extraction
15.14and chemical synthesis:
15.15(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
15.16opiate.
15.17(i) Excluding:
15.18(A) apomorphine;
15.19(B) thebaine-derived butorphanol;
15.20(C) dextrophan;
15.21(D) nalbuphine;
15.22(E) nalmefene;
15.23(F) naloxegol;
15.24(G) naloxone;
15.25(H) naltrexone; and
15.26(I) their respective salts;
15.27(ii) but including the following:
15.28(A) opium, in all forms and extracts;
15.29(B) codeine;
16.1(C) dihydroetorphine;
16.2(D) ethylmorphine;
16.3(E) etorphine hydrochloride;
16.4(F) hydrocodone;
16.5(G) hydromorphone;
16.6(H) metopon;
16.7(I) morphine;
16.8(J) oxycodone;
16.9(K) oxymorphone;
16.10(L) thebaine;
16.11(M) oripavine;
16.12(2) any salt, compound, derivative, or preparation thereof which is chemically equivalent
16.13or identical with any of the substances referred to in clause (1), except that these substances
16.14shall not include the isoquinoline alkaloids of opium;
16.15(3) opium poppy and poppy straw;
16.16(4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves
16.17(including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers
16.18and derivatives), and any salt, compound, derivative, or preparation thereof which is
16.19chemically equivalent or identical with any of these substances, except that the substances
16.20shall not include decocainized coca leaves or extraction of coca leaves, which extractions
16.21do not contain cocaine or ecgonine;
16.22(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid,
16.23or powder form which contains the phenanthrene alkaloids of the opium poppy).
16.24(c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
16.25of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule,
16.26whenever the existence of such isomers, esters, ethers and salts is possible within the specific
16.27chemical designation:
16.28(1) alfentanil;
16.29(2) alphaprodine;
16.30(3) anileridine;
17.1(4) bezitramide;
17.2(5) bulk dextropropoxyphene (nondosage forms);
17.3(6) carfentanil;
17.4(7) dihydrocodeine;
17.5(8) dihydromorphinone;
17.6(9) diphenoxylate;
17.7(10) fentanyl;
17.8(11) isomethadone;
17.9(12) levo-alpha-acetylmethadol (LAAM);
17.10(13) levomethorphan;
17.11(14) levorphanol;
17.12(15) metazocine;
17.13(16) methadone;
17.14(17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
17.15(18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic
17.16acid;
17.17(19) pethidine;
17.18(20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
17.19(21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
17.20(22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
17.21(23) phenazocine;
17.22(24) piminodine;
17.23(25) racemethorphan;
17.24(26) racemorphan;
17.25(27) remifentanil;
17.26(28) sufentanil;
17.27(29) tapentadol;
18.1(30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).
18.2(d) Unless specifically excepted or unless listed in another schedule, any material,
18.3compound, mixture, or preparation which contains any quantity of the following substances
18.4having a stimulant effect on the central nervous system:
18.5(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
18.6(2) methamphetamine, its salts, isomers, and salts of its isomers;
18.7(3) phenmetrazine and its salts;
18.8(4) methylphenidate;
18.9(5) lisdexamfetamine.
18.10(e) Unless specifically excepted or unless listed in another schedule, any material,
18.11compound, mixture, or preparation which contains any quantity of the following substances
18.12having a depressant effect on the central nervous system, including its salts, isomers, and
18.13salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible
18.14within the specific chemical designation:
18.15(1) amobarbital;
18.16(2) glutethimide;
18.17(3) secobarbital;
18.18(4) pentobarbital;
18.19(5) phencyclidine;
18.20(6) phencyclidine immediate precursors:
18.21(i) 1-phenylcyclohexylamine;
18.22(ii) 1-piperidinocyclohexanecarbonitrile;
18.23(7) phenylacetone.
18.24(f) Hallucinogenic substances Cannabis and cannabinoids:
18.25(1) nabilone;
18.26(2) unless specifically excepted or unless listed in another schedule, any natural material,
18.27compound, mixture, or preparation that contains any quantity of the following substances,
18.28their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever
18.29the existence of the isomers, esters, ethers, or salts is possible:
19.1(i) marijuana; and
19.2(ii) tetrahydrocannabinols naturally contained in a plant of the genus cannabis or in the
19.3resinous extractives of the plant.
19.4EFFECTIVE DATE.This section is effective August 1, 2020, and applies to crimes
19.5committed on or after that date.

19.6    Sec. 15. Minnesota Statutes 2018, section 152.11, is amended by adding a subdivision to
19.7read:
19.8    Subd. 5. Exception. References in this section to Schedule II controlled substances do
19.9not extend to marijuana or tetrahydrocannabinols.

19.10    Sec. 16. Minnesota Statutes 2018, section 152.12, is amended by adding a subdivision to
19.11read:
19.12    Subd. 6. Exception. References in this section to Schedule II controlled substances do
19.13not extend to marijuana or tetrahydrocannabinols.

19.14    Sec. 17. Minnesota Statutes 2018, section 152.125, subdivision 3, is amended to read:
19.15    Subd. 3. Limits on applicability. This section does not apply to:
19.16(1) a physician's treatment of an individual for chemical dependency resulting from the
19.17use of controlled substances in Schedules II to V of section 152.02;
19.18(2) the prescription or administration of controlled substances in Schedules II to V of
19.19section 152.02 to an individual whom the physician knows to be using the controlled
19.20substances for nontherapeutic purposes;
19.21(3) the prescription or administration of controlled substances in Schedules II to V of
19.22section 152.02 for the purpose of terminating the life of an individual having intractable
19.23pain; or
19.24(4) the prescription or administration of a controlled substance in Schedules II to V of
19.25section 152.02 that is not a controlled substance approved by the United States Food and
19.26Drug Administration for pain relief; or
19.27(5) the administration of medical cannabis under sections 152.21 to 152.37.

20.1    Sec. 18. Minnesota Statutes 2018, section 152.126, subdivision 1, is amended to read:
20.2    Subdivision 1. Definitions. (a) For purposes of this section, the terms defined in this
20.3subdivision have the meanings given.
20.4    (b) "Board" means the Minnesota State Board of Pharmacy established under chapter
20.5151.
20.6    (c) "Controlled substances" means those substances listed in section 152.02, subdivisions
20.73 to 6, and those substances defined by the board pursuant to section 152.02, subdivisions
20.87
, 8, and 12. For the purposes of this section, controlled substances includes butalbital and
20.9gabapentin but does not include medical cannabis under sections 152.21 to 152.37.
20.10    (d) "Dispense" or "dispensing" has the meaning given in section 151.01, subdivision
20.1130
. Dispensing does not include the direct administering of a controlled substance to a
20.12patient by a licensed health care professional.
20.13    (e) "Dispenser" means a person authorized by law to dispense a controlled substance,
20.14pursuant to a valid prescription. For the purposes of this section, a dispenser does not include
20.15a licensed hospital pharmacy that distributes controlled substances for inpatient hospital
20.16care or a veterinarian who is dispensing prescriptions under section 156.18.
20.17    (f) "Prescriber" means a licensed health care professional who is authorized to prescribe
20.18a controlled substance under section 152.12, subdivision 1 or 2.
20.19    (g) "Prescription" has the meaning given in section 151.01, subdivision 16a."
20.20Renumber the sections in sequence and correct the internal references
20.21Amend the title accordingly